Detalles de la búsqueda
1.
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Lancet Oncol
; 20(7): 998-1010, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31101489
2.
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Br J Haematol
; 184(2): 215-222, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30183069
3.
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Invest New Drugs
; 37(2): 297-306, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30132271
4.
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Blood
; 127(1): 79-86, 2016 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26472752
5.
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Am J Hematol
; 93(10): 1199-1206, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30016552
6.
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Br J Haematol
; 176(3): 412-420, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27982425
7.
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
Blood
; 125(15): 2336-43, 2015 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25696919
8.
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Blood
; 123(19): 2944-52, 2014 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24591201
9.
Molecular monitoring of response in patients with chronic myeloid leukemia.
Manag Care
; 22(7): 40, 50-61, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23936973
10.
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Blood
; 115(3): 475-80, 2010 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-19965689
11.
Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
Clin Cancer Res
; 27(1): 60-69, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32998965
12.
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-ß and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Neurooncol Adv
; 3(1): vdab058, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34056607
13.
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Lancet Haematol
; 8(4): e254-e266, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33631112
14.
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Invest New Drugs
; 27(5): 476-81, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18953490
15.
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
J Clin Oncol
; 37(12): 984-991, 2019 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30811293
16.
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Lancet Haematol
; 6(5): e254-e265, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30935953
17.
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 35(31): 3538-3546, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28862883
18.
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 16(4): 182-190.e1, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26875824
19.
Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study.
Ther Adv Hematol
; 4(3): 157-71, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23730494
20.
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
J Clin Oncol
; 31(1): 88-94, 2013 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23045577
Resultados
1 -
20
de 20
1
Próxima >
>>